A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with CDK4/6 inhibitor

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2024
This article has no abstract
Epistemonikos ID: 68e93a86e41f664006613984cdb85b0194c2158a
First added on: Jan 17, 2025